Protalix Biotherapeutics, Inc. (PLX)
2.095
+0.10
(+4.75%)
USD |
NYAM |
Jan 09, 13:19
Protalix Biotherapeutics Research and Development Expense (Annual): 12.97M for Dec. 31, 2024
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| PAVmed, Inc. | 5.932M |
| Denali Therapeutics, Inc. | 396.44M |
| AIM ImmunoTech, Inc. | 6.149M |
| Perspective Therapeutics, Inc. | 39.33M |
| Armata Pharmaceuticals, Inc. | 34.43M |